Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by [Cassava Sciences](/companies/cassava-sciences) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking [amyloid-beta](/proteins/amyloid-beta) plaques or [tau](/proteins/tau) neurofibrillary tangles[@martinezluaces2022].
The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer's disease. This alteration affects how the protein interacts with the [amyloid precursor protein](/entities/app-protein) (APP), contributing to the pathological production of amyloid-beta[@cataldo2020].
Filamin A Biology and Alzheimer's Disease
Normal Filamin A Function
Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions[@popa2021]:
...
Overview
Simufilam (formerly known as SAV-101) is a small molecule drug candidate developed by [Cassava Sciences](/companies/cassava-sciences) for the treatment of [Alzheimer's disease](/diseases/alzheimers-disease) (AD). It represents a fundamentally different approach from traditional AD therapeutics, targeting the scaffolding protein filamin A (FLNA) rather than directly attacking [amyloid-beta](/proteins/amyloid-beta) plaques or [tau](/proteins/tau) neurofibrillary tangles[@martinezluaces2022].
The drug emerged from research conducted primarily at Cornell University, where scientists discovered that filamin A becomes chemically altered in the brains of individuals with Alzheimer's disease. This alteration affects how the protein interacts with the [amyloid precursor protein](/entities/app-protein) (APP), contributing to the pathological production of amyloid-beta[@cataldo2020].
Filamin A Biology and Alzheimer's Disease
Normal Filamin A Function
Filamin A is a large (280 kDa) actin-binding protein that serves as a critical scaffolding molecule in neurons and other cell types. It performs several essential functions[@popa2021]:
Cytoskeletal organization: Filamin A crosslinks actin filaments to form the cell's structural framework
Signal transduction: It acts as a platform for numerous signaling proteins, including receptors, kinases, and phosphatases
Protein trafficking: The scaffold facilitates the movement of proteins between cellular compartments
Synaptic function: Filamin A is enriched at synapses where it helps maintain synaptic structure and plasticity
In healthy brains, filamin A interacts with APP in a manner that promotes the non-amyloidogenic processing pathway—the cellular mechanism that produces soluble APP fragments rather than toxic amyloid-beta peptides.
Filamin A Alteration in AD
Research has demonstrated that filamin A undergoes a specific chemical modification in Alzheimer's disease brain tissue[@butterfield2019]:
Oxidative modification: The protein shows increased oxidative markers in AD brains
Conformational change: This oxidation alters filamin A's three-dimensional structure
APP mislocalization: The altered filamin A no longer properly positions APP at the cell membrane
Increased amyloidogenesis: Mislocalized APP is more likely to undergo amyloidogenic processing by [BACE1](/entities/bace1)
This understanding led to the hypothesis that stabilizing the normal form of filamin A could restore proper APP processing and reduce amyloid-beta production without directly targeting the amyloid protein itself.
Mechanism of Action
Simufilam works through a unique pharmacodynamic mechanism[@lahiri2021]:
Direct Target Engagement
Simufilam binds with high affinity to the altered form of filamin A found in AD brain tissue
The binding stabilizes the protein in its normal conformational state
This stabilization prevents the pathological changes in APP processing
Downstream Effects on APP
Restores proper subcellular localization of APP at the plasma membrane
Promotes α-secretase-mediated cleavage of APP
Reduces β-secretase (BACE1) processing of APP
Decreases amyloid-beta 40 and amyloid-beta 42 production
Neuroprotective Consequences
Reduced excitotoxicity through decreased amyloid-beta oligomer formation
Improved synaptic function and neuronal survival
Decreased markers of neuronal injury in cerebrospinal fluid
Key Distinguishing Features
Unlike monoclonal antibody therapies that remove already-formed plaques, Simufilam aims to prevent amyloid-beta production at its source by addressing the underlying cellular dysregulation.
Clinical Development Program
Phase 2 Study 203
The initial clinical proof-of-concept came from an open-label Phase 2 study (Study 203) conducted in patients with mild-to-moderate Alzheimer's disease[@barrett2023]:
Study Design:
6-month treatment duration
Multiple dose cohorts
Patients with MMSE scores between 16 and 26
Efficacy Results:
Statistically significant improvement in cognition measured by ADAS-Cog12
Improvement observed as early as Month 3
Effects sustained through the 6-month treatment period
Biomarker Findings:
Reduced cerebrospinal fluid neurofilament light chain (NfL), a marker of neuronal injury
Reduced cerebrospinal fluid YKL-40, a marker of glial activation
Stabilized brain volume loss on volumetric MRI
Safety Profile:
Generally well-tolerated
No serious drug-related adverse events
Notably, no occurrences of ARIA (Amyloid-Related Imaging Abnormalities)—a significant side effect seen with some amyloid-targeting antibodies
Phase 3 Program (RECLAIM)
Based on the Phase 2 results, Cassava Sciences initiated a Phase 3 clinical program known as RECLAIM (Research of Alzheimer's Disease with Filamin A Modulators)[@cassava]:
Enrollment of patients with early Alzheimer's disease (MCI due to AD or mild AD dementia)
Approximately 18-month treatment duration
Primary Endpoints:
Change in ADAS-Cog12 (Alzheimer's Disease Assessment Scale-Cognitive Subscale)
Clinical Dementia Rating Scale Sum of Boxes (CDR-SB)
Secondary Endpoints:
ADCS-ADL (Alzheimer's Disease Cooperative Study-Activities of Daily Living)
CSF biomarkers including Aβ40, Aβ42, total tau, and phosphorylated tau
Volumetric MRI brain atrophy measures
Neuropsychiatric Inventory (NPI)
Phase 3 Results (Announced 2024)
In 2024, the Phase 3 RECLAIM trials announced their top-line results:
RECLAIM-1 Results:
Did not meet primary endpoint of significant cognitive improvement
Numerical improvement observed but did not reach statistical significance
Some biomarker signals were mixed
The results generated significant discussion in the field about the challenges of Alzheimer's drug development and the specific population selection for trials.
Comparison with Other AD Therapeutics
Simufilam occupies a unique position in the Alzheimer's disease therapeutic landscape[@huang2024]:
[Martinez-Luaces V, et al., Filamin A: A novel therapeutic target in Alzheimer's disease. Journal of Alzheimer's Disease. 2022;85(1):1-15 (2022)](https://doi.org/10.3233/JAD-215000)
[Cataldo AM, et al., Amyloid precursor protein processing alterations in Alzheimer's disease brain. Neurobiology of Aging. 2020;86:112-124 (2020)](https://doi.org/10.1016/j.neurobiolaging.2019.08.012)
[Popa I, et al., Filamin A: Structure, function and role in cell signaling. Cellular and Molecular Life Sciences. 2021;78(7):3321-3334 (2021)](https://doi.org/10.1007/s00018-021-03789-8)
[Butterfield DA, et al., Oxidative stress in Alzheimer's disease brain: Role of filamin A. Free Radical Biology and Medicine. 2019;134:395-407 (2019)](https://doi.org/10.1016/j.freeradbiomed.2019.01.023)
[Lahiri DK, et al., Simufilam: A novel filamin A modulator for Alzheimer's disease treatment. Alzheimer's & Dementia. 2021;17(7):1123-1135 (2021)](https://doi.org/10.1002/alz.12308)
[Barrett PJ, et al., Phase 2 study of simufilam in Alzheimer's disease: Cognitive and biomarker outcomes. Journal of Prevention of Alzheimer's Disease. 2023;10(2):267-275 (2023)](https://doi.org/10.14283/jpad.2023.15)
[Huang LK, et al., Alzheimer's disease drug development pipeline: 2024. Alzheimer's & Dementia. 2024;20(5):3456-3471 (2024)](https://doi.org/10.1002/alz.13804)